Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer

作者: Y Wang , H Xia , Z Zhuang , L Miao , X Chen

DOI: 10.1038/CDDIS.2014.186

关键词: Epithelial–mesenchymal transitionCancer researchTyrosine kinasemicroRNAGefitinibLung cancerCarcinogenesisErlotinibBiologyRNA interference

摘要: The involvement of Axl kinase in non-small cell lung cancer's (NSCLC) acquired resistance to tyrosine inhibitors (TKIs) gefitinib or erlotinib has been identified recently, but the mechanism by which contributes TKI is largely unknown. MicroRNAs (miRNAs) repress gene expression and their critical role tumorigenesis implicated. To investigate miRNAs Axl-mediated resistance, we examined miRNA changes gefitinib-resistant cancers. A panel kinase-altered was identified. In this study, validate report that miR-374a miR-548b modulated have essential roles cycle arrest, gefitinib-induced apoptosis, epithelial-to-mesenchymal transition, migration cancer cells vitro vivo targeting Wnt5a CCNB1 genes, respectively. Of clinical significance, high low are associated with poor disease-free survival postoperatively. These findings indicate modulation specific may provide a therapeutic target treat reverse NSCLC future.

参考文章(27)
Martin D. Jansson, Anders H. Lund, MicroRNA and cancer Molecular Oncology. ,vol. 6, pp. 590- 610 ,(2012) , 10.1016/J.MOLONC.2012.09.006
Cuihua Yang, Cheng Wang, Xi Chen, Sidi Chen, Yanni Zhang, Feng Zhi, Junjun Wang, Limin Li, Xiaojun Zhou, Nanyun Li, Hao Pan, Junfeng Zhang, Ke Zen, Chen-Yu Zhang, Chunni Zhang, Identification of seven serum microRNAs from a genome‐wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas International Journal of Cancer. ,vol. 132, pp. 116- 127 ,(2013) , 10.1002/IJC.27657
Takayuki Kosaka, Yasushi Yatabe, Hideki Endoh, Kimihide Yoshida, Toyoaki Hida, Masahiro Tsuboi, Hirohito Tada, Hiroyuki Kuwano, Tetsuya Mitsudomi, Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib Clinical Cancer Research. ,vol. 12, pp. 5764- 5769 ,(2006) , 10.1158/1078-0432.CCR-06-0714
L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Science Translational Medicine. ,vol. 3, ,(2011) , 10.1126/SCITRANSLMED.3002003
Zhenfeng Zhang, Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D Levine, Jin Kyung Rho, Yun Jung Choi, Chang-Min Choi, Sang-We Kim, Se Jin Jang, Young Soo Park, Woo Sung Kim, Dae Ho Lee, Jung-Shin Lee, Vincent A Miller, Maria Arcila, Marc Ladanyi, Philicia Moonsamy, Charles Sawyers, Titus J Boggon, Patrick C Ma, Carlota Costa, Miquel Taron, Rafael Rosell, Balazs Halmos, Trever G Bivona, Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer Nature Genetics. ,vol. 44, pp. 852- 860 ,(2012) , 10.1038/NG.2330
J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Janne, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science. ,vol. 316, pp. 1039- 1043 ,(2007) , 10.1126/SCIENCE.1141478
William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus, Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain PLoS Medicine. ,vol. 2, pp. e73- ,(2005) , 10.1371/JOURNAL.PMED.0020073
George A. Calin, Carlo M. Croce, MicroRNA signatures in human cancers Nature Reviews Cancer. ,vol. 6, pp. 857- 866 ,(2006) , 10.1038/NRC1997